ClinicalTrials.gov
ClinicalTrials.gov Menu

Swedish Iodine in Pregnancy and Development in Children (SWIDDICH) Study (SWIDDICH)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT02378246
Recruitment Status : Recruiting
First Posted : March 4, 2015
Last Update Posted : August 15, 2018
Sponsor:
Collaborator:
Sahlgrenska University Hospital, Sweden
Information provided by (Responsible Party):
Göteborg University

Brief Summary:

THE ULTIMATE GOAL of this project is to answer the question "In MILD IODINE DEFICIENCY (ID), should 150 μg iodine/day be administered to pregnant women with a normal diet, to attain a normal cognitive development of the fetus or is there no cognitive deficit from mild ID and no extra iodine is needed?". To answer this question, the investigators planned a randomized, placebo-controlled trial of iodine supplementation during pregnancy in Sweden (SWIDDICH) with the follow-up of childrens' COGNITIVE DEVELOPMENT at 18 months, 3.5, 7 and 14 years.

Iodine deficiency (ID) is associated with thyroid morbidity and, especially in children, with impaired cognitive development. Sweden introduced iodine fortification of table salt 1936 and mental retardation due to severe ID is eradicated. Is mild ID during pregnancy also eradicated? If not, is this of importance? A national study performed by the investigators in 2007 showed iodine sufficiency in general population, but there are no pregnancy data. Local studies have raised concerns for mild ID during pregnancy in Sweden and a trans-sectional national study is currently ongoing.

The burning question for Sweden and the whole world is: is mild ID during pregnancy of importance for the developing brain of the fetus? Two large observational studies have shown association between mild ID during pregnancy and lower verbal IQ or educational performance at school-aged children. The world needs a randomized placebo-controlled trial (RTC) comparing the cognitive outcome in children exposed to mild ID during fetal life with children exposed to normal iodine levels during fetal life.

Our HYPOTHESIS is that pregnant women in Sweden have mild ID and that children exposed to mild ID during fetal life have a lower cognitive development, compared to children to mothers taking 150 ug iodine supplementation during pregnancy.

The MAIN AIM of the SWIDDICH trial is to determine if children exposed to mild iodine deficiency (ID) during fetal life achieve worse cognitive development compared to children exposed to normal iodine status reached by maternal iodine supplementation.


Condition or disease Intervention/treatment Phase
Thyroid Gland; Node Pregnancy Cognitive Developmental Delay Dietary Supplement: Iodine Dietary Supplement: Placebo Not Applicable

  Show Detailed Description

Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 1275 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Triple (Participant, Care Provider, Outcomes Assessor)
Primary Purpose: Prevention
Official Title: The Importance of Iodine During Pregnancy for Future Brain Function : a Randomized Placebo-controlled Trial. Swedish Iodine in Pregnancy and Development in Children (SWIDDICH) Study
Actual Study Start Date : November 2012
Estimated Primary Completion Date : June 2025
Estimated Study Completion Date : June 2032

Resource links provided by the National Library of Medicine

Drug Information available for: Iodine

Arm Intervention/treatment
Experimental: Iodine containing multivitamin
multivitamin tablet containing 150 ug iodine, 1 tablet daily
Dietary Supplement: Iodine
We use multivitamin tablets one with 150 microgram iodine for Active comparator and one without iodine as placebo

Placebo Comparator: Placebo: non-iodine containing multivitamin
non-iodine containing multivitamin, 1 tablet daily
Dietary Supplement: Placebo
multivitamin tablets without iodine




Primary Outcome Measures :
  1. Intelligence quotient (IQ) at 7 years, WISC IV [ Time Frame: when the child is at the age of 7 years ± 3 months ]
    Wechsler Intelligence Scale for Children - Fourth Edition; IQ with sub-domains


Secondary Outcome Measures :
  1. Psychomotor development at 18 months, ASQ-3 [ Time Frame: when the child is at the age of 18 months ± 1 month ]
    Ages & Stages Questionnaire - Third Edition; a questionnaire filled in by parents

  2. Intelligence quotient (IQ) at 3.5 years, WPPSI IV [ Time Frame: when the child is at the age of 3,5 years ± 2 months ]
    Wechsler Preschool and Primary Scale of Intelligence - Fourth Edition; IQ with sub-domains

  3. Intelligence quotient (IQ) at 14 years, WISC IV [ Time Frame: when the child is at the age of 14 years ± 6 months ]
    Wechsler Intelligence Scale for Children - Fourth Edition; IQ with sub-domains

  4. Behavioral problems at 3.5 years, CBCL [ Time Frame: when the child is at the age of 3,5 years ± 2 months ]
    Child Behavior Checklist questionnaire filled in by parents

  5. Behavioral problems at 7 years, CBCL [ Time Frame: when the child is at the age of 7 years ± 3 months ]
    Child Behavior Checklist questionnaire filled in by parents

  6. Behavioral problems at 14 years, CBCL [ Time Frame: when the child is at the age of 14 years ± 6 months ]
    Child Behavior Checklist questionnaire filled in by parents

  7. ADHD-related problems at 7 years, FTF [ Time Frame: when the child is at the age of 7 years ± 3 months ]
    Nordic Questionnaire 5-15 (FTF) filled in by parents

  8. ADHD-related problems at 14 years, FTF [ Time Frame: when the child is at the age of 14 years ± 6 months ]
    Nordic Questionnaire 5-15 (FTF) filled in by parents

  9. Motor skills at 7 years, Movement ABC [ Time Frame: when the child is at the age of 7 years ± 3 months ]
    Movement ABC test performed by a physiotherapist

  10. Brain development at 7 years, MRI [ Time Frame: when the child is at the age of 7 years ± 3 months ]
    Magnetic Resonance Imaging; manual and automatic volumetry

  11. Brain development at 7 years, MRI [ Time Frame: when the child is at the age of 14 years ± 6 months ]
    Magnetic Resonance Imaging; manual and automatic volumetry

  12. Urinary iodine concentration (UIC) in the mother, 1st trimester [ Time Frame: 10±2 weeks (pregnancy) ]
  13. Urinary iodine concentration (UIC) in the mother, 2nd trimester [ Time Frame: 26±2 weeks (pregnancy) ]
  14. Urinary iodine concentration (UIC) in the mother, 3rd trimester [ Time Frame: 36±2 weeks (pregnancy) ]
  15. Thyreoglobulin concentration in serum, in the mother, 1st trimester [ Time Frame: 10±2 weeks (pregnancy) ]
  16. Thyreoglobulin in serum, in the mother, 2nd trimester [ Time Frame: 26±2 weeks (pregnancy) ]
  17. Thyreoglobulin in serum, in the mother, 3rd trimester [ Time Frame: 36±2 weeks (pregnancy) ]
  18. Thyroid stimulating hormon concentration in serum, in the mother, 1st trimester [ Time Frame: 10±2 weeks (pregnancy) ]
  19. Thyroid stimulating hormon concentration in serum, in the mother, 2nd trimester [ Time Frame: 26±2 weeks (pregnancy) ]
  20. Thyroid stimulating hormon concentration in serum, in the mother, 3rd trimester [ Time Frame: 36±2 weeks (pregnancy) ]
  21. Free thyroxine concentration in serum, in the mother, 1st trimester [ Time Frame: 10±2 weeks (pregnancy) ]
  22. Free thyroxine concentration in serum, in the mother, 2nd trimester [ Time Frame: 26±2 weeks (pregnancy) ]
  23. Free thyroxine concentration in serum, in the mother, 3rd trimester [ Time Frame: 36±2 weeks (pregnancy) ]
    Free thyroxine concentration, serum

  24. Anti-TPO in the mother, 1st trimester [ Time Frame: 10±2 weeks (pregnancy) ]
    Thyroid peroxidase antibody titer, plasma

  25. Anti-TPO in the mother, 2nd trimester [ Time Frame: 26±2 weeks (pregnancy) ]
    Thyroid peroxidase antibody titer, plasma

  26. Anti-TPO in the mother, 3rd trimester [ Time Frame: 36±2 weeks (pregnancy) ]
    Thyroid peroxidase antibody titer, plasma

  27. B12 in the mother, 1st trimester [ Time Frame: 10±2 weeks (pregnancy) ]
    Vitamin B12, serum

  28. B12 in the mother, 2nd trimester [ Time Frame: 26±2 weeks (pregnancy) ]
    Vitamin B12, serum

  29. B12 in the mother, 3rd trimester [ Time Frame: 36±2 weeks (pregnancy) ]
    Vitamin B12, serum

  30. Selenium in the mother, 1st trimester [ Time Frame: 10±2 weeks (pregnancy) ]
    Selenium, serum

  31. Selenium in the mother, 2nd trimester [ Time Frame: 26±2 weeks (pregnancy) ]
    Selenium, serum

  32. Selenium in the mother, 3rd trimester [ Time Frame: 36±2 weeks (pregnancy) ]
    Selenium, serum

  33. Iron in the mother, 1st trimester [ Time Frame: 10±2 weeks (pregnancy) ]
    Iron, serum

  34. Iron in the mother, 2nd trimester [ Time Frame: 26±2 weeks (pregnancy) ]
    Iron, serum

  35. Iron in the mother, 3rd trimester [ Time Frame: 36±2 weeks (pregnancy) ]
    Iron, serum

  36. Milk iodine concentration (MIC) in colostrum [ Time Frame: within 5 days after delivery ]
  37. Urinary iodine concentration (UIC) in the newborn [ Time Frame: within 5 days after delivery ]
  38. Urinary iodine concentration (UIC) in the mother [ Time Frame: within 5 days after delivery ]
  39. Urinary iodine concentration (UIC) at 3.5 years [ Time Frame: when the child is at the age of 3,5 years ± 2 months ]
  40. Urinary iodine concentration (UIC) at 7 years [ Time Frame: when the child is at the age of 7 years ± 3 months ]
  41. Urinary iodine concentration (UIC) at 14 years [ Time Frame: when the child is at the age of 14 years ± 6 months ]
  42. Thyroid stimulating hormone, dry blood spot (DBS), in the newborn [ Time Frame: within 5 days after delivery ]
  43. TSH at 7 years [ Time Frame: when the child is at the age of 7 years ± 3 months ]
    Thyroid stimulating hormone, dry blood spot (DBS)

  44. TSH at 14 years [ Time Frame: when the child is at the age of 14 years ± 6 months ]
    Thyroid stimulating hormone, dry blood spot (DBS)

  45. TG at 7 years [ Time Frame: when the child is at the age of 7 years ± 3 months ]
    Thyreoglobulin, dry blood spot (DBS)

  46. TG at 14 years [ Time Frame: when the child is at the age of 14 years ± 6 months ]
    Thyreoglobulin, dry blood spot (DBS)

  47. FT4 at 7 years [ Time Frame: when the child is at the age of 7 years ± 3 months ]
    Free thyroxine, dry blood spot (DBS)

  48. FT4 at 14 years [ Time Frame: when the child is at the age of 14 years ± 6 months ]
    Free thyroxine, dry blood spot (DBS)

  49. Deiodinases at 7 years [ Time Frame: when the child is at the age of 7 years ± 3 months ]
    Dry blood spot (DBS)

  50. Deiodinases at 14 years [ Time Frame: when the child is at the age of 14 years ± 6 months ]
    Dry blood spot (DBS)



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years to 40 Years   (Adult)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   No
Criteria

PREGNANT WOMEN

Inclusion criteria

  • Pregnant, week <12
  • Age 18-40 years
  • Intent of a full term pregnancy
  • Agreement of taking no iodide containing supplements during the study except for study supplement

Exclusion Criteria

  • Known current thyroid disease
  • Risk factors for thyroid disease (history or heredity for thyroid, other autoimmune disease or symptoms of hypo-/hyperthyroidism) where the TSH is abnormal
  • Possibility to not attend to the protocol according to the investigator's opinion
  • Less than 6 months from previous pregnancy or lactating period
  • Vegan

CONTROL WOMEN

Inclusion criteria

  • Age 18-40 years
  • Agreeing not to take iodide containing supplements 1 week prior to the collecting of the samples.

Exclusion criteria

  • Current thyroid disease
  • Risk factors for thyroid disease (history or heredity for thyroid or other autoimmune disease or symptoms of hypo-/hyperthyroidism) where the TSH is abnormal
  • Possibility to not attend to the protocol according to the investigator's opinion
  • Currently pregnant or lactating
  • Less than 6 months from previous pregnancy or lactating period
  • Vegans

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02378246


Contacts
Contact: Sofia Manousou, PhD student +46700595310 sofia.manousou@vgergion.se
Contact: Helena Filipsson, Ass Prof 0046-705833398 helena.nystrom@vgregion.se

Locations
Sweden
Umeå Universitet, Department of Clinical Sciences Recruiting
Umea, Västerbotten, Sweden, 901 85
Contact: Magnus Domellöf, Professor    090-7852128    magnus.domellof@umu.se   
Contact: Anna Chmielewska, MD, PhD    090-7852370    anna.chmielewska@umu.se   
Sahlgrenska University Hospital Recruiting
Gothenburg, Sweden, 413 45
Contact: Helena Filipsson, MD, PhD    0705-833398    helena.filipsson@gu.se   
Contact: Sofia Manousou, MD    0700-5953310    sofia.manousou@vgregion.se   
Sub-Investigator: Lena Hulthén, Senior Prof         
Sub-Investigator: Robert Eggertsen, Prof         
Principal Investigator: Helena Filipsson Nyström, Ass Prof         
Sub-Investigator: Carl-Johan Törnhage, Docent         
Sub-Investigator: Birgitta Johansson, Docent         
Sub-Investigator: Helge Malmgren, Senior Prof         
Linköping University Hospital Not yet recruiting
Linkoping, Sweden
Contact: Kerstin Gutefeldt         
Completed
Skövde, Sweden
Sponsors and Collaborators
Göteborg University
Sahlgrenska University Hospital, Sweden
Investigators
Principal Investigator: Helena Filipsson Nyström, Ass Prof Center for Endocrinology and Metabolism, SAhlgrenska University Hospital

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: Göteborg University
ClinicalTrials.gov Identifier: NCT02378246     History of Changes
Other Study ID Numbers: 13031305
First Posted: March 4, 2015    Key Record Dates
Last Update Posted: August 15, 2018
Last Verified: August 2018
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Undecided
Plan Description: This has not yet been discussed by the study group.

Keywords provided by Göteborg University:
Iodine
Double-Blind Method
Randomized Controlled Tria
Cognitive Development

Additional relevant MeSH terms:
Iodine
Cadexomer iodine
Anti-Infective Agents, Local
Anti-Infective Agents
Trace Elements
Micronutrients
Growth Substances
Physiological Effects of Drugs